Clinical Trials | A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with Relapsed/Refractory Multiple Myeloma. The purpose of this study is to evaluate the safety and efficacy of GC012F (AZD0120), a novel CART cell therapy targeting both CD19 and BCMA in adult subjects with relapsed/refractory MM. A single-arm design was chosen for the study due to the lack of established standard of care options for use as a concurrent control for this patient population. This study will include two parts with different doses of study drug. In the Phase 1b part of the study, the safety of 2+ doses of GC012F (AZD0120) will be evaluated and the recommended Phase 2 dose (RP2D) selected. In the Phase 2 part of the study, efficacy of the selected RP2D of GC012F (AZD0120) will be further evaluated, as will the continued safety evaluation of the product. UVA will be participating in both dose escalation and dose expansion. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. The duration of your participation in the study may last about 15 years (including long-term follow-up). However, this will depend on how you respond to the study drug and may continue until your disease gets worse, you develop bad side effects, you decide to no longer take part in the study, or your study doctor decides that the study is not in your best interest. Additional information found here: https://clinicaltrials.gov/study/NCT05850234 For questions, contact: [email protected]